C4 Therapeutics (CCCC) Net Income towards Common Stockholders (QoQ) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.39% |
| Dec 31, 2025 | 36.69% |
| Sep 30, 2025 | -23.62% |
| Jun 30, 2025 | 1.15% |
| Mar 31, 2025 | 23.87% |
| Dec 31, 2024 | -40.16% |
| Sep 30, 2024 | -39.23% |
| Jun 30, 2024 | 37.53% |
| Mar 31, 2024 | 18.40% |
| Dec 31, 2023 | -28.55% |
| Sep 30, 2023 | 24.73% |
| Jun 30, 2023 | -3.28% |
| Mar 31, 2023 | 6.47% |
| Dec 31, 2022 | -16.36% |
| Sep 30, 2022 | -18.90% |
| Jun 30, 2022 | 15.00% |
| Mar 31, 2022 | -101.94% |
| Dec 31, 2021 | 36.56% |
| Sep 30, 2021 | -9.31% |
| Jun 30, 2021 | -7.67% |
| Mar 31, 2021 | -83.44% |
| Dec 31, 2020 | 57.73% |
| Sep 30, 2020 | -97.41% |
| Jun 30, 2020 | 2.30% |
| Mar 31, 2020 | -39.91% |
| Dec 31, 2019 | 0.70% |